KRYS Krystal Biotech Forecast, Technical & Fundamental Analysis

KRYS's Stochastic Oscillator sits in overbought zone for 1 day

Expect a price pull-back in the near future.

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

KRYS broke above its upper Bollinger Band on December 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for KRYS just turned positive on December 23, 2025. Looking at past instances where KRYS's MACD turned positive, the stock continued to rise in of 60 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in of 316 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 217 cases where KRYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.402) is normal, around the industry mean (26.541). P/E Ratio (37.675) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (20.121) is also within normal values, averaging (311.015).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.